Nyström Johanna, Svennerholm Ann-Mari
Department of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy of Göteborg University, Box 435, 405 30 Göteborg, Sweden.
Vaccine. 2007 Mar 30;25(14):2591-8. doi: 10.1016/j.vaccine.2006.12.026. Epub 2006 Dec 26.
In the present study, we evaluated the capacity of Helicobacter pylori adhesin A (HpaA), a H. pylori specific colonization factor, to induce therapeutic protection against H. pylori infection in mice. We found that oral immunization of H. pylori infected mice with HpaA induced protection, i.e. significant reduction in bacterial load in the stomach. This was even more pronounced when a combination of HpaA and urease was used. The protection was strongly related to specific mucosal CD4+ T cell responses with a Th1 profile as well as to mucosal IgA responses locally in the stomach. These findings suggest that HpaA is a promising vaccine candidate antigen for use in a therapeutic vaccine against H. pylori.
在本研究中,我们评估了幽门螺杆菌粘附素A(HpaA)(一种幽门螺杆菌特异性定植因子)诱导小鼠抵抗幽门螺杆菌感染的治疗性保护能力。我们发现,用HpaA对感染幽门螺杆菌的小鼠进行口服免疫可诱导保护作用,即胃内细菌载量显著降低。当使用HpaA和脲酶的组合时,这种保护作用更加明显。这种保护作用与具有Th1型谱的特异性黏膜CD4 + T细胞反应以及胃局部的黏膜IgA反应密切相关。这些发现表明,HpaA是用于抗幽门螺杆菌治疗性疫苗的一种有前景的候选抗原。